MIR4697: MIR4697 is a long non-coding RNA (lncRNA) that has been identified as a key competing endogenous RNA (ceRNA) for miRNA-mRNA in lung adenocarcinoma [PMC5259593]. It has also been found to be upregulated in cancerous tissues compared to adjacent noncancerous tissues [PMC5769367]. In ovarian cancer cells, down-regulation of the MIR4697 host gene (MIR4697HG) promotes tumor growth and metastasis by reducing levels of matrix metalloproteinase-9, p-ERK, and phosphorylated AKT [PMC7027163]. In a study on a Chinese population, a significant association was found between a single nucleotide polymorphism (SNP) in MIR4697 (rs329648) and the susceptibility to Parkinson's disease [PMC6115491]. MIR4697 is one of the twelve loci that have shown genome-wide significant association with Parkinson's disease risk in multiple independent samples [PMC7369933]. Additionally, MIR4697 is one of the candidate PD-risk genes identified by a meta-analysis of genome-wide association studies [PMC6216208]. In lung adenocarcinoma, three differentially expressed lncRNAs have been revealed as prognostic biomarkers, including MIR4697 [PMC6471985]. Overall, these findings highlight the potential role of MIR4697 in cancer development and Parkinson's disease susceptibility.